| Editor’s Note: FierceBiotech will not publish on Monday in observance of Martin Luther King Jr. Day, but we’ll be back in your inbox on Tuesday, Jan. 21. Today's Rundown Frazier closes $617M life sciences fund, creating scope for bigger bets Durect's painkiller gets evenly split decision from expert panel JPM: Biotech, VC execs on where the industry should look beyond cancer After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO This immune checkpoint could be a new target against cancer, autoimmune diseases Foxconn backs digital X-ray startup Nanox’s $26M round EuroBiotech Report—MorphoSys-Incyte, Adaptimmune deal, Galapagos, BioNTech and Ipsen FiercePharmaAsia—Astellas' cell therapy deal; Takeda's €398M tax bill; Lilly-shared PD-1 in NSCLC Chutes & Ladders—Bluebird picks up Heffron as European chief Featured Story | | | Friday, January 17, 2020 Frazier Healthcare Partners has closed a $617 million life sciences fund, setting it up to place another set of bets spanning from company creation through public investments. Two-thirds of Frazier Life Sciences X will go into seed and series A rounds. |
|
|---|
|
| Thank you to Rho for sponsoring this year's JPM 2020 coverage. |
Top Stories Friday, January 17, 2020 A FDA advisory committee has issued an evenly split decision on Durect’s extended-release formulation of bupivacaine. Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir on the basis of the available evidence. Friday, January 17, 2020 SAN FRANCISCO—Oncology is clearly a major medical and societal issue: a major killer that, while predominately affecting the older population, can strike the young through a mixture of environmental factors or a genetic lottery. It’s no wonder we struggle to even call it by its name, preferring just the "big C." Friday, January 17, 2020 China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. Thursday, January 16, 2020 Inhibitors against PD-1 and CTLA-4 have become well-established anti-cancer treatments. Now, a research team led by Dartmouth College suggests another immune checkpoint, which acts as a “brake” on naive T cells' activation, could also serve as a therapeutic target for cancer and autoimmune diseases. Friday, January 17, 2020 Nanox, an Israeli medical imaging company, has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed. Thursday, January 16, 2020 In this week's EuroBiotech Report, MorphoSys lands Incyte deal, Adaptimmune teams with Astellas and Galapagos bags fibrosis options. Friday, January 17, 2020 Astellas teamed up with Adaptimmune to develop CAR-T and TCR therapies. Takeda faces a surprising Irish tax bill linked to the Shire breakup fee AbbVie paid years ago. Innovent's Eli Lilly-partnered PD-1, Tyvyt, hits its goal in a phase 3 frontline non-small cell lung cancer trial in China. And more. Friday, January 17, 2020 Bluebird Bio taps Heffron as Euro chief; Hildemann joins struggling Ipsen as CMO; Ivenix names Hansen as CEO. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|---|
|
Resources Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Sponsored by: DocuSign A digital transformation is taking place in the life sciences industry, from research laboratories to manufacturing facilities. But there has always been a gap in these technologies. Download the whitepaper to learn how this challenge was addressed. Sponsored by: DocuSign This paper discusses some of the challenges that the GDPR will introduce, with a particular focus on its requirements for obtaining verifiable, unambiguous consent. Sponsored by: DocuSign Download this paper to learn how you can fully digitize all paper processes. By doing so, you will see shorter cycle times, reduced development costs, and greater customer satisfaction. Sponsored by: Benchling As emerging modalities transform the needs of life science R&D, how can biotech and pharma companies use modern software approaches to increase productivity and reach breakthroughs faster? Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: ICON Clinical Research Ltd The beginning of this digital transformation is well underway and is likely to accelerate. Read our white paper, “Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D,” to learn more. Sponsored by: snapIoT, Inc. Download this white paper and read the expert feedback that snapIoT has gathered from industry thought leaders on the evolution, evaluation, and use of telemedicine solutions in clinical trials. Sponsored by: EVERSANA How are your launch strategies can convert “innovation” into value for patients? Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: Outer Edge Technology, LLC Why companies leverage the expertize of industry focused cloud service providers to design and build quality systems and facilitate the FDA Validation of Mission Critical Apps in the Cloud. Sponsored by: Colorcon Learn more: Best practices for defending supply chain security and compliance by efficiently managing product authentication. Sponsored by: Metabolon Small or emerging pharmaceutical and biotech companies pursuing novel molecules and targets have two important goals: achieve clinical success and attract new rounds of funding. While there’s never a guarantee of either, certain actions can influence the outcome in your favor. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Asia-Pacific Healthcare Compliance Certificate Program March 9-12, 2020 11th Annual SCOPE Summit: Summit for Clinical Ops Executives February 18-21, 2020 | Orlando, FL BIO International Convention June 8-11, 2020 | San Diego, CA Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. Middle East Healthcare Compliance Certificate Program March 23-26, 2020 | 